← Back to Clinical Trials
Recruiting NCT03469609

NCT03469609 Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds ("MUC-FIRE" Trial)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03469609
Status Recruiting
Phase
Sponsor University of Leipzig
Condition Enterostomy
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2018-06-18
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 12 Months
Study Type INTERVENTIONAL
Interventions
mucous fistula refeeding

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2018-06-18 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this study is to demonstrate that mucous fistula refeeding between enterostomy creation and enterostomy closure reduces the time to full enteral feeds after enterostomy closure compared to standard of care.

Eligibility Criteria

Inclusion Criteria: 1. Infants \< 366 days, 2. Ileostomy / Jejunostomy, 3. double loop enterostomies and split enterostomies (with mucous fistula) 4. Signed written informed consent obtained by parents/legal guardians and willingness of parents/legal guardians to comply with treatment and follow-up procedures of their child Exclusion Criteria: 1. resection of ileocecal valve, 2. colostomy, 3. small bowel atresia, 4. multiple ostomies (more than just an enterostomy and a mucous fistula), 5. chromosomal abnormalities (if known at the time of randomization), 6. Hirschsprung's disease, 7. participation in another drug-intervention study 8. Intestinal perforation due to a hemodynamic heart defect

Contact & Investigator

Central Contact

Martin Lacher, Prof. Dr. med.

✉ muc-fire-leipzig@medizin.uni-leipzig.de

📞 +49-341-97

Principal Investigator

Omid Madadi-Sanjani, PD Dr. med.

PRINCIPAL INVESTIGATOR

University Medical Center Hamburg-Eppendorf (UKE), Department of Pediatric Surgery

Frequently Asked Questions

Who can join the NCT03469609 clinical trial?

This trial is open to participants of all sexes, up to 12 Months, studying Enterostomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03469609 currently recruiting?

Yes, NCT03469609 is actively recruiting participants. Contact the research team at muc-fire-leipzig@medizin.uni-leipzig.de for enrollment information.

Where is the NCT03469609 trial being conducted?

This trial is being conducted at Graz, Austria, Vienna, Austria, Tübingen, Germany, München, Germany and 11 additional locations.

Who is sponsoring the NCT03469609 clinical trial?

NCT03469609 is sponsored by University of Leipzig. The principal investigator is Omid Madadi-Sanjani, PD Dr. med. at University Medical Center Hamburg-Eppendorf (UKE), Department of Pediatric Surgery. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology